LEAP-015 (MK-7902-015)

Name No. For Patients with Purpose
LEAP-015 (MK-7902-015) 21-34

Previously untreated advanced/ metastatic HER-2 negative gastric/ gasto-esophageal junction (GEJ) cancer.

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer.


DESTINY DS8201-A-U306  

Name No. For Patients with Purpose
DESTINY DS8201-A-U306   21-07

HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.


BMS CA209-8HW

Name No. For Patients with Purpose
BMS CA209-8HW 18-08

Metastatic colorectal cancer (mCRC)

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).


Astellas 8951-CL-5201

Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM)


Lithium

Name No. For Patients with Purpose
Lithium 11-32

Advanced oesophago-gastric or colorectal cancer

The purpose of this trial is to determine the safety and efficacy of the drug lithium and the optimum dose when used with standard chemotherapy.


MK3475-937 (KEYNOTE-937)

Name No. For Patients with Purpose
MK3475-937 (KEYNOTE-937) 19-07

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).